comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 12:56:54 - browse：3

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

WSS

David Sabatini, ex

As AI regulations shape up, health tech startups beg for clarity

New study raises questions about niacin and heart health

Startling documents reveal new facets of Sacklers' opioid empire

Reporting on presidential health from Reagan to Trump and Biden

Surprise medical billing ban raises prices elsewhere

Wikipedia

comprehensive

leisure time

Continuity nursing helped my family in our darkest PICU moments

First Opinion Podcast: What happens when kids become caregivers?

Trump demands the U.S. pay no more for drugs than other countries … again

Secretariat’s lessons for human medicine

The cancer drug shortage isn’t new — and neither are the solutions

MD Anderson's Padmanee Sharma responds to research credit suit

Hollywood unions extend contract negotiations for actors

Surprise medical billing ban raises prices elsewhere

Tori Bowie and the unacceptable rates of Black maternal death

Researchers tackle phage therapy hurdles for wider adoption

leisure time

New CMS data security rules will hurt Medicare, Medicaid research

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

FDA warns medical device makers about rise in fabricated data

Measles policy set amid Florida outbreak alarms vaccine proponents

Focused ultrasound for uterine fibroids: an uphill battle

Prosthetic arm enables patients to feel the objects they grip

focus

entertainment

knowledge

focus